Analysis of the Pathogenesis of IBD

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a heterogeneous state of chronic intestinal inflammation. It has become a global health problem with an increasing incidence. Although the etiology of IBD is unknown, considerable progress has been made in recent years in elucidating the pathogenesis of the disease. Studies have shown that the pathogenesis of IBD is related to the host's genetic susceptibility, gut microbiota, other environmental factors and immune abnormalities. A comprehensive understanding of these pathogenetic mechanisms of IBD is essential for the development of novel therapeutic strategies to target the disease.

Fig. 1. The etiology of IBD involves a complex interaction between genetic, environmental or microbial factors and immune responses. Fig. 1. Interaction of various factors contributing to chronic intestinal inflammation in a genetically susceptible host. (Sartor, 2006)

IBD Pathogenesis Analysis Services

Ace Therapeutics specializes in the field of IBD and provides reliable pathogenesis analysis services. Through high genomic approaches, studies of environmental changes, molecular analyses of the gut microbiota, and comprehensive analyses of the interactions between the innate and adaptive immune responses, we help our clients gain more detailed information about their composition, function, and interactions.

We offer a variety of in vivo, in vitro and ex vivo models to study the pathogenesis of IBD, to identify novel predictive or prognostic biomarkers, and to develop new therapies.

Analysis of IBD Immunopathogenesis

We investigate the precise molecular mechanisms underlying the immunopathogenesis of IBD by identifying novel immunogenetic parameters, characterizing heterogeneity parameters, and performing comprehensive multiparametric assessments of different aspects of known disease biology. These multidisciplinary approaches allow us to help our clients study all aspects of IBD immunopathogenesis.

Gut Microbiota Analysis in IBD

We provide germ-free animal models, germ-free housing, and comprehensive microbiome analysis services to help clients study the gut microbiota and host-microbe interactions in IBD. With a comprehensive portfolio of microbiome-specific services, Ace Therapeutics leverages microbiome insights to meet the evolving needs of IBD drug R&D programs.

Analysis of the Genetics of IBD

Ace Therapeutics provides comprehensive genetic research services to help clients analyze the genetic background of IBD. Using DNA analysis and sequencing technology platforms, our experienced team of experts can analyze gene-gene interactions, gene-pathway interactions, and gene-environment interactions. We aim to improve the understanding of IBD pathological mechanisms required for the development of new therapeutics.

Analysis of the Role of Intestinal Barrier in IBD

Our team of experts can provide in-depth characterization of intestinal epithelial barrier genes in IBD animals. Incorporating genetic and transcriptomic approaches to help clients better understand the genes and intestinal epithelial barrier components associated with the disease. We have extensive experience in the analysis of intestinal epithelial barrier dysfunction in IBD.

Why Choose Us?

Expertise. Our team consists of leading experts in the fields of immunology and gastroenterology with extensive experience in the study of IBD pathogenesis and development of therapeutic approaches.
Customized models and advanced technologies. We use multidisciplinary approaches and representative IBD models to provide precise and actionable insights.
Research-oriented approach. Our services are based on the latest research in IBD pathogenesis and therapeutics.

By evaluating the associations between proinflammatory and anti-inflammatory immune cells and molecules and various genetic susceptibility, intestinal microbiota, and environmental factors, Ace Therapeutics helps clients to gain a comprehensive understanding of the pathogenesis of IBD and explore therapeutic avenues/targets. Contact us today to discuss your project and learn how our expertise can contribute to your success.

Reference

Sartor, R. B. (2006). Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature clinical practice Gastroenterology & hepatology, 3(7), 390-407.

! For research use only, not intended for any clinical use.